Chemotherapy News and Research

Latest Chemotherapy News and Research

Robotic retroperitoneal lymph node dissection (RPLND) for testicular cancer: an interview with Dr. Stephen Williams of St. Joseph Hospital in Orange

Robotic RPLND utilizes laparoscopy combined with robotic technology to perform dissection and removal of lymph node tissue in the retroperitoneum both as a staging as well as therapeutic procedure for patients with testicular cancer.

10 Jul 2013

Advanced genetics technologies may help predict patient outcomes in people with ALL

New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes for patients with a particularly aggressive form of acute lymphocytic leukemia (ALL).

10 Jul 2013

Innovative vaccine could offer hope to patients with advanced ovarian cancer

Loyola University Medical Center is conducting a clinical trial of an innovative vaccine that could offer hope to patients with advanced ovarian cancer.

10 Jul 2013

MerTK inhibition in leukocytes decreases tumor growth and metastasiss

The tyrosine kinase MerTK plays a prominent role in the body's immune response. MerTK signaling helps "calm" the body's first line of immunity, the macrophage, while it performs the routine duties - clearing cells that die and healing damaged tissue.

9 Jul 2013

Soy peptide injection dramatically reduces colon cancer metastasis in mice

After a recent University of Illinois study showed that injection of the soy peptide lunasin dramatically reduced colon cancer metastasis in mice, the researchers were eager to see how making lunasin part of the animals' daily diet would affect the spread of the disease.

9 Jul 2013

Anti-cancer compounds offer hope for treating breast cancer

Melbourne researchers have discovered that anti-cancer compounds currently in clinical trials for some types of leukaemia could offer hope for treating the most common type of breast cancer.

9 Jul 2013

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

COTI-2 is a computer-designed small molecule that was discovered by our artificial intelligence drug discovery platform called CHEMSAS.

8 Jul 2013

Study: ChemoFx chemoresponse assay can help identify platinum resistance in primary ovarian cancer

Precision Therapeutics, a leading life-science company dedicated to the improvement of patient outcomes in personalized medicine, today announced findings that support the ChemoFx chemoresponse assay as a tool to aid in the identification of platinum resistance in primary ovarian cancer, according to a presentation at the Annual Meeting of The Western Association of Gynecologic Oncologists June 26-29, in Seattle, Washington.

8 Jul 2013

AIFA grants market access for CTI's PIXUVRI to treat patients with aggressive B-cell NHL

Cell Therapeutics, Inc. today announced that the Company has been granted market access by the Italian Medicines Agency for the medicinal product PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy).

8 Jul 2013

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

Imaging techniques in cancer medicine provide far more than merely information on the scale and location of cancerous ulcers. There are modern methods that additionally characterise the tumour cells precisely, for instance by specific molecules they carry on their surface. Such additional information gives doctors key clues as to the precise cancer type and enables them to predict the probability that a patient will respond to a particular form of therapy.

6 Jul 2013

CorMedix's Neutrolin catheter lock solution receives CE Mark approval

CorMedix Inc. today announced that it has received CE Mark approval for Neutrolin, a catheter lock solution, for patients with central venous catheters on hemodialysis secondary to advanced chronic kidney disease.

6 Jul 2013

Oncologist urges drug companies to include key information in cancer drug labels

In the July 10th issue of The New England Journal of Medicine, Dr. Basch calls for pharmaceutical manufacturers to collect rigorous information on how drugs impact symptoms and quality of life starting early in drug development, and for the U.S. Food and Drug Administration (FDA) to include this information in drug labels.

5 Jul 2013

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

ERYTECH, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces a fast take-off of its Phase IIb study in Acute Myeloid Leukemia.

4 Jul 2013

MGN1703 drug provides a new treatment approach to colorectal cancer

New data on an emerging treatment that aims to fight colorectal cancer by stimulating the immune system have been presented at the ESMO 15th World Congress on Gastrointestinal Cancer.

4 Jul 2013

GAPVAC aims to develop personalized therapeutic vaccines for cancer

A highly innovative project supported by a €6 million European Union Framework 7 (EU FP7) program grant to develop a novel class of therapeutic cancer vaccines is now under way.

4 Jul 2013

Professor receives grant to explore therapeutic agent, treatment method for brain cancer

The problem with cancer treatments designed to kill a tumor is that they can kill the patient's quality of life as well. Now a Florida State University College of Medicine researcher is shifting the focus from eradicating brain tumors to managing them.

4 Jul 2013

Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

For patients with advanced gastric cancer, treatment with chemotherapy after surgery can reduce the risk of cancer related death by 34% over five years compared to surgery alone, researchers said at the 15th ESMO World Congress in Gastrointestinal Cancer.

4 Jul 2013

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for obinutuzumab (GA101) and granted Priority Review for GA101 in the treatment of chronic lymphocytic leukemia, one of the most common forms of blood cancer, based on final Stage 1 data from the pivotal CLL11 trial.

3 Jul 2013

Abiraterone can prolong overall survival and delay severe pain in prostate cancer patients

Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms or so far none at all, and in whom chemotherapy is not yet indicated.

3 Jul 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

Robotic retroperitoneal lymph node dissection (RPLND) for testicular cancer: an interview with Dr. Stephen Williams of St. Joseph Hospital in Orange

Advanced genetics technologies may help predict patient outcomes in people with ALL

Innovative vaccine could offer hope to patients with advanced ovarian cancer

MerTK inhibition in leukocytes decreases tumor growth and metastasiss

Soy peptide injection dramatically reduces colon cancer metastasis in mice

Anti-cancer compounds offer hope for treating breast cancer

Soligenix announces personalized medicine collaboration with SciClone

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

Study: ChemoFx chemoresponse assay can help identify platinum resistance in primary ovarian cancer

AIFA grants market access for CTI's PIXUVRI to treat patients with aggressive B-cell NHL

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

CorMedix's Neutrolin catheter lock solution receives CE Mark approval

Oncologist urges drug companies to include key information in cancer drug labels

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

MGN1703 drug provides a new treatment approach to colorectal cancer

GAPVAC aims to develop personalized therapeutic vaccines for cancer

Professor receives grant to explore therapeutic agent, treatment method for brain cancer

Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

Abiraterone can prolong overall survival and delay severe pain in prostate cancer patients

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in